New Dual-Action antibody targets tumors in early trial
NCT ID NCT06635785
First seen Nov 10, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody designed to block two cancer growth signals (PD-1 and VEGF). The main goals are to find the safest dose and check for side effects. About 387 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Cancer Institute
RECRUITINGOrlando, Florida, 32804, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Henry Ford Health
RECRUITINGDetroit, Michigan, 48202, United States
-
Highlands Oncology Group
RECRUITINGSpringdale, Arkansas, 72762, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
MedStar Georgetown University Hospital
RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
Memorial Healthcare System
RECRUITINGHollywood, Florida, 33021, United States
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
-
Norton Cancer Center
RECRUITINGLouisville, Kentucky, 40202, United States
-
Novant Health Cancer Institute
RECRUITINGWinston-Salem, North Carolina, 27103, United States
-
Ocala Oncology Center PL DBA Florida Cancer Affiliates
RECRUITINGOcala, Florida, 34474, United States
-
Prisma Health
RECRUITINGGreenville, South Carolina, 29605, United States
-
The Ohio State University James Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The Tisch Cancer Institute, Mount Sinai Medical Center
NOT_YET_RECRUITINGNew York, New York, 10029, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
-
University of Florida UF Health Cancer Center
RECRUITINGGainesville, Florida, 32610, United States
-
University of Michigan Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of North Carolina at Chapel Hill Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
University of Utah Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.